{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:35Z","timestamp":1787169515442,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"\n Background:<\/jats:title>\n The impact of propranolol on patients with cirrhosis and refractory ascites is controversial. We conducted a nationwide longitudinal cohort study to compare the survival between patients with cirrhosis and refractory ascites, with and without using propranolol.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Data of patients with cirrhosis and refractory ascites using propranolol, and controls matched by age and gender, were extracted from The National Health Insurance Research Database of Taiwan. The baseline demographic characteristics were compared between groups. Cox regression analysis was used to examine the predictors of mortality.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n In this study, 1788 patients were enrolled in each group; 1304 patients (72.9%) in the propranolol group and 1445 patients (80.8%) in the control group died (\n P<\/jats:italic>\n < 0.001). The mean survival was 34.3 \u00b1 31.2 months in the propranolol group and 20.8 \u00b1 26.6 months in the control group (\n P<\/jats:italic>\n < 0.001). Propranolol (hazard ratio [HR]: 0.60, 95% confidence interval [CI]: 0.55\u20130.64,\n P<\/jats:italic>\n < 0.001), statins (HR: 0.43, 95% CI: 0.34\u20130.56,\n P<\/jats:italic>\n < 0.001), age (HR: 1.02, 95% CI: 1.01\u20131.02,\n P<\/jats:italic>\n < 0.001), and diabetes mellitus (HR: 1.14, 95% CI: 1.05\u20131.24,\n P<\/jats:italic>\n = 0.002) were the independent predictors for mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Use of propanolol was associated with reduced mortality, compared with controls, in this nationwide cohort of patients with cirrhosis and refractory ascites.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/sjg.sjg_586_21","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T02:42:16Z","timestamp":1646793736000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Propranolol use in patients with cirrhosis and refractory ascites"],"prefix":"10.4103","volume":"28","author":[{"given":"Yen-Chun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Da","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Shuo","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240829","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D\u2019Amico","year":"1986","journal-title":"Dig Dis Sci"},{"key":"R2-5-20240829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.1840070124","article-title":"Compensated cirrhosis: Natural history and prognostic factors","volume":"7","author":"Gin\u00e9s","year":"1987","journal-title":"Hepatology"},{"key":"R3-5-20240829","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","article-title":"Natural history of patients hospitalized for management of cirrhotic ascites","volume":"4","author":"Planas","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-5-20240829","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJM198112033052302","article-title":"Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A controlled study","volume":"305","author":"Lebrec","year":"1981","journal-title":"N Engl J Med"},{"key":"R5-5-20240829","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0140-6736(91)93125-S","article-title":"Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis","volume":"337","author":"P\u00e9rez-Ayuso","year":"1991","journal-title":"Lancet"},{"key":"R6-5-20240829","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","article-title":"Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers","volume":"107","author":"Hern\u00e1ndez-Gea","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R7-5-20240829","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","article-title":"beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: A meta-analysis","volume":"29","author":"Senzolo","year":"2009","journal-title":"Liver Int"},{"key":"R8-5-20240829","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"R9-5-20240829","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2011.01.034","article-title":"Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study","volume":"55","author":"Serst\u00e9","year":"2011","journal-title":"J Hepatol"},{"key":"R10-5-20240829","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","article-title":"Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis","volume":"146","author":"Mandorfer","year":"2014","journal-title":"Gastroenterology"},{"key":"R11-5-20240829","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.28352","article-title":"Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients","volume":"63","author":"Bossen","year":"2016","journal-title":"Hepatology"},{"key":"R12-5-20240829","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation","volume":"64","author":"Leithead","year":"2015","journal-title":"Gut"},{"key":"R13-5-20240829","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2016.09.007","article-title":"Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study","volume":"152","author":"Tsai","year":"2017","journal-title":"Gastroenterology"},{"key":"R14-5-20240829","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis","volume":"37","author":"Abraldes","year":"2003","journal-title":"Hepatology"},{"key":"R15-5-20240829","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/liv.13409","article-title":"Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites","volume":"37","author":"Onali","year":"2017","journal-title":"Liver Int"},{"key":"R16-5-20240829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjms.2015.11.018","article-title":"The beneficial effect of beta-blockers in patients with cirrhosis, portal hypertension and ascites","volume":"351","author":"Aday","year":"2016","journal-title":"Am J Med Sci"},{"key":"R17-5-20240829","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2014.06.012","article-title":"Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure","volume":"61","author":"Jalan","year":"2014","journal-title":"J Hepatol"},{"key":"R18-5-20240829","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","article-title":"Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure","volume":"64","author":"Mookerjee","year":"2016","journal-title":"J Hepatol"},{"key":"R19-5-20240829","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00042737-199907000-00013","article-title":"Intestinal permeability in liver cirrhosis: Relationship with severe septic complications","volume":"11","author":"Campillo","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R20-5-20240829","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J Hepatol"},{"key":"R21-5-20240829","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/liv.13119","article-title":"Effect of propranolol on survival in patients with decompensated cirrhosis: A nationwide study based Danish patient registers","volume":"36","author":"Bang","year":"2016","journal-title":"Liver Int"},{"key":"R22-5-20240829","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/jcm8050573","article-title":"Low-dose propranolol as secondary prophylaxis for varix bleeding decreases mortality and rebleeding rate in patients with tense ascites","volume":"8","author":"Park","year":"2019","journal-title":"J Clin Med"},{"key":"R23-5-20240829","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","article-title":"Innate and adaptive inflammation as a therapeutic target in vascular disease: The emerging role of statins","volume":"63","author":"Tousoulis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R24-5-20240829","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"R25-5-20240829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41575-018-0045-2","article-title":"Novel perspectives in the management of decompensated cirrhosis","volume":"15","author":"Bernardi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R26-5-20240829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"R27-5-20240829","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J Hepatol"},{"key":"R28-5-20240829","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1111\/liv.12782","article-title":"Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: A meta-analysis of randomized trials","volume":"35","author":"Thiele","year":"2015","journal-title":"Liver Int"},{"key":"R29-5-20240829","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.jhepr.2019.12.001","article-title":"Beta-blockers in cirrhosis: Evidence-based indications and limitations","volume":"2","author":"Rodrigues","year":"2020","journal-title":"JHEP Rep"},{"key":"R31-5-20240829","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.1840050313","article-title":"Portal pressure, presence of gastroesophageal varices and variceal bleeding","volume":"5","author":"Garcia-Tsao","year":"1985","journal-title":"Hepatology"},{"key":"R32-5-20240829","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.22341","article-title":"Comorbidity and survival of Danish cirrhosis patients: A nationwide population-based cohort study","volume":"48","author":"Jepsen","year":"2008","journal-title":"Hepatology"},{"key":"R33-5-20240829","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/cid\/cit603","article-title":"Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: A nationwide cohort study","volume":"57","author":"Huang","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R34-5-20240829","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/hep.27228","article-title":"Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C","volume":"60","author":"Elkrief","year":"2014","journal-title":"Hepatology"},{"key":"R35-5-20240829","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R36-5-20240829","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2009.05851.x","article-title":"Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis","volume":"24","author":"Toshikuni","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R37-5-20240829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1478-3231.2005.01181.x","article-title":"Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients","volume":"26","author":"Sol\u00e0","year":"2006","journal-title":"Liver Int"},{"key":"R38-5-20240829","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus\u2013related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_586_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:48Z","timestamp":1787166468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_586_21"}},"subtitle":["A nationwide study"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_586_21","relation":{},"ISSN":["1319-3767"],"issn-type":[{"value":"1319-3767","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}